Survey of the Impact of COVID-19 on Chronic Liver Disease Patient Care Experiences and Outcomes

Jiang, Shirley; Schwab, Katerina; Enns, Robert; Ko, Hin Hin

doi:10.1093/jcag/gwac022

Cited by 3 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,9 Early experiences of telehealth use in gastroenterology clinics during the COVID-19 pandemic have reported high levels of satisfaction from both patients and providers. 2,10,11 There was a corresponding rise in clinic capacity, decline in waiting lists, and increase in clinic revenue. 12 In patients managed by telehealth, medication adherence was non-inferior to those with in-person visits.…”

Section: Introductionmentioning

confidence: 99%

Patient and Provider Perspectives on Telemedicine use in Canadian Gastroenterology Clinics during the COVID-19 pandemic: A Survey study

Tomaszewski,

X. Jiang,

Jae Kim

et al. 2024

J Surg Res

View full text Add to dashboard Cite

BackgroundTelemedicine has revolutionized access to medical care. This was particularly palpable during the COVID pandemic and within gastroenterology. Telehealth can improve access to patients remotely, and lead to high patient and clinician satisfaction. However, questions remain surrounding patient selection and provider considerations. We conducted a Canadian study to examine patient and provider preferences and experiences in telehealth. MethodsAn anonymous online survey was conducted amongst patients of an urban gastroenterology practice, as well as Canadian gastroenterologists, evaluating experiences and preferences in utility of telemedicine. ResultsOf 1236 patients contacted, 181 (15%) respondents were aged 18-89, 60% were female, and 58% had in ammatory bowel disease (IBD). Patient satisfaction with telehealth was high across all characteristics. Patients used both phone calls (61%) and video/audio applications (50%); higher use of phone calls was associated with older age (p = 0.02).Patients living more than 30km from clinic and with IBD were more likely to prefer telehealth visits (p < 0.01). Most providers (96%) and patients (96%) believed that telehealth use should continue for certain patients or follow up visits after the pandemic. Of 100 providers contacted, 25 respondents reported using phone calls (96%) and video/audio applications (44%). Providers perceived follow up of benign endoscopic pathology (96%) and general follow up visits (92%) to be most suitable for telehealth. ConclusionCanadian gastroenterology providers and patients appreciate telehealth and favor continued use after the pandemic.Consideration of patient factors such as age, distance, health issue, and follow up status can further optimize ongoing telehealth options.

show abstract

Section: Introductionmentioning

confidence: 99%

Patient and Provider Perspectives on Telemedicine use in Canadian Gastroenterology Clinics during the COVID-19 pandemic: A Survey study

Tomaszewski,

X. Jiang,

Jae Kim

et al. 2024

J Surg Res

View full text Add to dashboard Cite

show abstract

Patient and provider perspectives on telemedicine use in Canadian gastroenterology clinics during the COVID-19 pandemic: a survey study

Tomaszewski,

Jiang,

Kim

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Telemedicine has revolutionized access to medical care. This was particularly palpable during the COVID pandemic and within gastroenterology. Telehealth can improve access to patients remotely, and lead to high patient and clinician satisfaction. However, questions remain surrounding patient selection and provider considerations. We conducted a Canadian study to examine patient and provider preferences and experiences in telehealth. Methods An anonymous online survey was conducted amongst patients of an urban gastroenterology practice, as well as Canadian gastroenterologists, evaluating experiences and preferences in utility of telemedicine. Results Of 1236 patients contacted, 181 (15%) respondents were aged 18–89, 60% were female, and 58% had inflammatory bowel disease (IBD). Patient satisfaction with telehealth was high across all characteristics. Patients used both phone calls (61%) and video/audio applications (50%); higher use of phone calls was associated with older age (p = 0.02). Patients living more than 30km from clinic and with IBD were more likely to prefer telehealth visits (p < 0.01). Most providers (96%) and patients (96%) believed that telehealth use should continue for certain patients or follow up visits after the pandemic. Of 100 providers contacted, 25 respondents reported using phone calls (96%) and video/audio applications (44%). Providers perceived follow up of benign endoscopic pathology (96%) and general follow up visits (92%) to be most suitable for telehealth. Conclusion Canadian gastroenterology providers and patients appreciate telehealth and favor continued use after the pandemic. Consideration of patient factors such as age, distance, health issue, and follow up status can further optimize ongoing telehealth options.

show abstract

Potential risk of liver injury in epileptic patients during COVID-19 pandemic

Tabrizi¹,

Sharifi-Razavi²

2022

World J Virol

View full text Add to dashboard Cite

Most of the antiseizure medications (ASMs) are metabolized in liver and many of them particularly first-generation ASMs have the potential to increase liver enzymes or induce liver injury. Hence, treatment of new onset seizures or epilepsy by ASMs during the course of coronavirus disease 2019 (COVID-19), which could potentially be complicated by hepatic dysfunction, is a challenging clinical issue. Intravenous form of levetiracetam which has no significant hepatic metabolism or drug-drug interaction is often a favorable option to control seizures in acute phase of COVID-19. Administration of enzyme inducer ASMs and valproate with the well-known hepatotoxicity and common drug interactions is not generally recommended. In patients with epilepsy who are under control with potentially hepatotoxic ASMs, close observation and cautious dose reduction or drug switch should be considered if any evidence of hepatic impairment exists. However, risks of possible breakthrough seizures should be weighed against benefits of lowering the hazard of liver injury. In patients with epilepsy who receive polytherapy with ASMs, transient dose modification with the tendency to increase the dose of ASMs with more favorable safety profile and less drug interaction and decrease the dose of drugs with main hepatic metabolism, high protein binding, potential to cause liver injury and known drug-drug reaction should be considered. Finally, decision making should be individualized based on patients’ conditions and course of illness.

show abstract

Survey of the Impact of COVID-19 on Chronic Liver Disease Patient Care Experiences and Outcomes

Cited by 3 publications

References 56 publications

Patient and Provider Perspectives on Telemedicine use in Canadian Gastroenterology Clinics during the COVID-19 pandemic: A Survey study

Patient and Provider Perspectives on Telemedicine use in Canadian Gastroenterology Clinics during the COVID-19 pandemic: A Survey study

Patient and provider perspectives on telemedicine use in Canadian gastroenterology clinics during the COVID-19 pandemic: a survey study

Potential risk of liver injury in epileptic patients during COVID-19 pandemic

Contact Info

Product

Resources

About